DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
| Ano de defesa: | 2026 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | |
| Tipo de documento: | Dissertação |
| Tipo de acesso: | Acesso aberto |
| Idioma: | por |
| Instituição de defesa: |
Faculdade Israelita de Ciências da Saúde Albert Einstein
|
| Programa de Pós-Graduação: |
Acadêmico em Ciências da Saúde
|
| Departamento: |
Não Informado pela instituição
|
| País: |
Brasil
|
| Palavras-chave em Português: | |
| Palavras-chave em Inglês: | |
| Link de acesso: | https://repositorio.einstein.br/publicacao/172733 |
Resumo: | Introduction: Multiple sclerosis is the most frequent disabling non-traumatic neurological disease in young adults of working age. New, more effective drugs, especially for patients with highly active disease, have been incorporated into the Clinical Protocol and Therapeutic Guidelines of the Brazilian Unified Health System updated in 2021. The use of these highly effective drugs, such as natalizumab and alemtuzumab, is associated with a better prognosis. Despite the high cost of multiple sclerosis treatment for the Brazilian Unified Health System, there are no national studies evaluating the impact of this update on the pattern of medication dispensing. Purpose: To compare the pattern of medication dispensing for multiple sclerosis before and after the 2021 update of the Clinical Protocol and Therapeutic Guidelines; to analyze regional inequalities in the dispensing of disease-modifying drugs; to evaluate the relationship between the distance traveled by patients from their municipality of residence to the dispensing center and the dispensing of highly effective therapies in the Brazilian Unified Health System, using big data tools. Methods: An observational study based on administrative data from authorizations for highly complex outpatient procedures in the Brazilian Unified Health System Outpatient Information System, covering the period from 2019 to 2023, including patients diagnosed with multiple sclerosis. The following variables were analyzed: National Health Card number, disease-modifying drug, municipality of residence, and municipality of the dispensing center. The pattern of medication dispensing was evaluated using time series and quasi-Poisson regression models, with a descriptive and comparative approach between the periods before and after the 2021 protocol update, at the national, regional, and state levels. The distance traveled between the municipality of residence and the dispensing center was estimated using a geographic routing tool. Statistical analysis included augmented Dickey-Fuller, Cox-Stuart, Fisher’s g, Kruskal-Wallis, and Spearman correlation tests. Analyses were performed using R software (p<0.05). Results: Between 2019 and 2023, the number of multiple sclerosis patients treated by the Brazilian Unified Health System increased by 25.91%, with 71.98% being women in 2023. After the 2021 protocol update, a heterogeneous change in the pattern of medication dispensing in Brazil was observed. There was an increase in the dispensing of natalizumab (+44.5%), fingolimod (+15.8%), teriflunomide (+32.5%), and dimethyl fumarate (+53.1%), concomitant with a reduction in beta-interferons (-40.3%) and glatiramer acetate (-27.6%) (all with p<0.001). Regionally, there was an increase in the dispensing of natalizumab in all regions, with the North (+82%; p=0.042) and Northeast (+52%; p=0.039) standing out. The reduction in beta-interferons was significant only in the North region (-41.9%; p=0.049). The greatest distance traveled by patients was observed in the Central-West region (median: 234.06km [129.99-375.36]). In the analysis by federative units, no association was observed between the distance traveled by patients and the proportion of natalizumab dispensing (?=0.157; p=0.434). In the Amazon Basin, the greatest distance traveled by patients was recorded in Amazonas (414.79 km [154.82–807.57]), with no association with the proportion of natalizumab dispensing (?=0.36; p=0.444). Conclusions: The 2021 protocol update had a heterogeneous impact on the dispensing of disease-modifying drugs in Brazil, highlighting persistent regional inequalities in access to multiple sclerosis treatment. The absence of an association between the distance traveled by patients and the dispensing of more effective therapies suggests that structural, organizational, and professional training factors exert a more relevant influence on access to these treatments than geographical distance. |
| id |
HAE-1_8f9e3386ef1bc8ee9fa5f3f63d2916cb |
|---|---|
| oai_identifier_str |
oai:repositorio.einstein.br:172733 |
| network_acronym_str |
HAE-1 |
| network_name_str |
Repositório Einstein de Produção Intelectual (REPI) |
| repository_id_str |
|
| spelling |
porDISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de SaúdeDispensing of disease-modifying therapies for multiple sclerosis in Brazil following the 2021 clinical protocol and therapeutic guidelines: a big data observational analysis of the Brazilian Unified Health SystemIntroduction: Multiple sclerosis is the most frequent disabling non-traumatic neurological disease in young adults of working age. New, more effective drugs, especially for patients with highly active disease, have been incorporated into the Clinical Protocol and Therapeutic Guidelines of the Brazilian Unified Health System updated in 2021. The use of these highly effective drugs, such as natalizumab and alemtuzumab, is associated with a better prognosis. Despite the high cost of multiple sclerosis treatment for the Brazilian Unified Health System, there are no national studies evaluating the impact of this update on the pattern of medication dispensing. Purpose: To compare the pattern of medication dispensing for multiple sclerosis before and after the 2021 update of the Clinical Protocol and Therapeutic Guidelines; to analyze regional inequalities in the dispensing of disease-modifying drugs; to evaluate the relationship between the distance traveled by patients from their municipality of residence to the dispensing center and the dispensing of highly effective therapies in the Brazilian Unified Health System, using big data tools. Methods: An observational study based on administrative data from authorizations for highly complex outpatient procedures in the Brazilian Unified Health System Outpatient Information System, covering the period from 2019 to 2023, including patients diagnosed with multiple sclerosis. The following variables were analyzed: National Health Card number, disease-modifying drug, municipality of residence, and municipality of the dispensing center. The pattern of medication dispensing was evaluated using time series and quasi-Poisson regression models, with a descriptive and comparative approach between the periods before and after the 2021 protocol update, at the national, regional, and state levels. The distance traveled between the municipality of residence and the dispensing center was estimated using a geographic routing tool. Statistical analysis included augmented Dickey-Fuller, Cox-Stuart, Fisher’s g, Kruskal-Wallis, and Spearman correlation tests. Analyses were performed using R software (p<0.05). Results: Between 2019 and 2023, the number of multiple sclerosis patients treated by the Brazilian Unified Health System increased by 25.91%, with 71.98% being women in 2023. After the 2021 protocol update, a heterogeneous change in the pattern of medication dispensing in Brazil was observed. There was an increase in the dispensing of natalizumab (+44.5%), fingolimod (+15.8%), teriflunomide (+32.5%), and dimethyl fumarate (+53.1%), concomitant with a reduction in beta-interferons (-40.3%) and glatiramer acetate (-27.6%) (all with p<0.001). Regionally, there was an increase in the dispensing of natalizumab in all regions, with the North (+82%; p=0.042) and Northeast (+52%; p=0.039) standing out. The reduction in beta-interferons was significant only in the North region (-41.9%; p=0.049). The greatest distance traveled by patients was observed in the Central-West region (median: 234.06km [129.99-375.36]). In the analysis by federative units, no association was observed between the distance traveled by patients and the proportion of natalizumab dispensing (?=0.157; p=0.434). In the Amazon Basin, the greatest distance traveled by patients was recorded in Amazonas (414.79 km [154.82–807.57]), with no association with the proportion of natalizumab dispensing (?=0.36; p=0.444). Conclusions: The 2021 protocol update had a heterogeneous impact on the dispensing of disease-modifying drugs in Brazil, highlighting persistent regional inequalities in access to multiple sclerosis treatment. The absence of an association between the distance traveled by patients and the dispensing of more effective therapies suggests that structural, organizational, and professional training factors exert a more relevant influence on access to these treatments than geographical distance.Introdução: A esclerose múltipla é a doença neurológica não traumática incapacitante mais frequente em adultos jovens, em idade economicamente ativa. Novas drogas de maior eficácia, especialmente para pacientes com doença altamente ativa, foram incorporadas ao Protocolo Clínico e Diretrizes Terapêuticas do Sistema Único de Saúde atualizado em 2021. O uso dessas drogas de alta eficácia, como natalizumabe e alentuzumabe, está associado a melhor prognóstico. Apesar do alto custo do tratamento da esclerose múltipla para o Sistema Único de Saúde, não há estudos nacionais que avaliem o impacto dessa atualização sobre o padrão de dispensação de medicamentos. Objetivos: Comparar o padrão de dispensação de medicamentos para esclerose múltipla antes e após a atualização do Protocolo Clínico e Diretrizes Terapêuticas de 2021; analisar desigualdades regionais na dispensação de drogas modificadoras de doença; e avaliar a relação entre a distância percorrida pelos pacientes do município de residência ao centro de dispensação e a dispensação de terapias de alta eficácia no Sistema Único de Saúde, utilizando ferramentas de big data. Métodos: Estudo observacional baseado em dados administrativos das autorizações de procedimentos ambulatoriais de alta complexidade do Sistema de Informação Ambulatorial do Sistema Único de Saúde, referente ao período de 2019 a 2023, incluindo pacientes com diagnóstico de esclerose múltipla. Foram analisadas as seguintes variáveis: número do Cartão Nacional de Saúde, droga modificadora de doença, município de residência e município do centro de dispensação. O padrão de dispensação de medicamentos foi avaliado por meio de séries temporais e modelos de regressão quasi-Poisson, com abordagem descritiva e comparativa entre os períodos pré e pós-atualização do protocolo de 2021, nos níveis nacional, regional e estadual. A distância percorrida entre o município de residência e o centro de dispensação foi estimada por ferramenta de roteamento geográfico. A análise estatística incluiu testes Dickey-Fuller aumentado, Cox-Stuart, Fisher’s g, Kruskal-Wallis e correlação de Spearman. As análises foram realizadas no software R (p<0,05). Resultados: Entre 2019 e 2023, o número de pacientes com esclerose múltipla atendidos pelo Sistema Único de Saúde aumentou 25,91%, sendo 71,98% mulheres em 2023. Após a atualização do protocolo de 2021, observou-se mudança heterogênea no padrão de dispensação de medicamentos no Brasil. Houve aumento na dispensação de natalizumabe (+44,5%), fingolimode (+15,8%), teriflunomida (+32,5%) e fumarato de dimetila (+53,1%), concomitante à redução de betainterferonas (-40,3%) e acetato de glatiramer (-27,6%) (todos com p<0,001). Regionalmente, houve aumento na dispensação de natalizumabe em todas as regiões, com destaque para o Norte (+82%; p=0,042) e Nordeste (+52%; p=0,039). A redução das betainterferonas foi significativa apenas na região Norte (-41,9%; p=0,049). A maior distância percorrida pelos pacientes foi observada na região Centro-Oeste (mediana: 234,06 km [129,99-375,36]). Na análise por unidades federativas, não se observou associação entre a distância percorrida pelos pacientes e a proporção de dispensação de natalizumabe (?=0,157; p=0,434). Na Bacia Amazônica, a maior distância percorrida pelos pacientes foi registrada no Amazonas (414,79 km [154,82–807,57]), sem associação com a proporção de dispensação de natalizumabe (?=0,36; p=0,444). Conclusões: A atualização do protocolo de 2021 impactou de forma heterogênea a dispensação de drogas modificadoras de doença no Brasil, evidenciando desigualdades regionais persistentes no acesso ao tratamento da esclerose múltipla. A ausência de associação entre a distância percorrida pelos pacientes e a dispensação de terapias de maior eficácia sugere que fatores estruturais, organizacionais e de capacitação profissional exerçam influência mais relevante no acesso a esses tratamentos do que a distância geográfica.Big dataEsclerose múltiplaProtocolos clínicosGuia de prática clínicaNatalizumabBig dataMultiple sclerosisClinical protocolsNatalizumabinfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/publishedVersionLivia Almeida Dutrahttp://lattes.cnpq.br/2916631594056232http://lattes.cnpq.br/2955600971230359Alexandre Coelho MarquesFaculdade Israelita de Ciências da Saúde Albert EinsteinAcadêmico em Ciências da SaúdeBrasil2026https://repositorio.einstein.br/publicacao/172733oai:repositorio.einstein.br:172733reponame:Repositório Einstein de Produção Intelectual (REPI)instname:Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)instacron:SBIBAEinfo:eu-repo/semantics/openAccessRepositório InstitucionalPRIhttps://repositorio.einstein.br/oai || https://api.einstein.br/prd/plataformacientifica/sgpcri/api/oai2repositorioinstitucional@einstein.bropendoar:2026-02-27T00:00Repositório Einstein de Produção Intelectual (REPI) - Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)falseoai:repositorio.einstein.br:172733 |
| dc.title.por.fl_str_mv |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| dc.title.alternative.eng.fl_str_mv |
Dispensing of disease-modifying therapies for multiple sclerosis in Brazil following the 2021 clinical protocol and therapeutic guidelines: a big data observational analysis of the Brazilian Unified Health System |
| title |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| spellingShingle |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde Alexandre Coelho Marques Big data Esclerose múltipla Protocolos clínicos Guia de prática clínica Natalizumab Big data Multiple sclerosis Clinical protocols Natalizumab |
| title_short |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| title_full |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| title_fullStr |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| title_full_unstemmed |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| title_sort |
DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde |
| author |
Alexandre Coelho Marques |
| author_facet |
Alexandre Coelho Marques |
| author_role |
author |
| dc.contributor.advisor1.fl_str_mv |
Livia Almeida Dutra |
| dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/2916631594056232 |
| dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/2955600971230359 |
| dc.contributor.author.fl_str_mv |
Alexandre Coelho Marques |
| contributor_str_mv |
Livia Almeida Dutra |
| dc.subject.por.fl_str_mv |
Big data Esclerose múltipla Protocolos clínicos Guia de prática clínica Natalizumab |
| topic |
Big data Esclerose múltipla Protocolos clínicos Guia de prática clínica Natalizumab Big data Multiple sclerosis Clinical protocols Natalizumab |
| dc.subject.eng.fl_str_mv |
Big data Multiple sclerosis Clinical protocols Natalizumab |
| description |
Introduction: Multiple sclerosis is the most frequent disabling non-traumatic neurological disease in young adults of working age. New, more effective drugs, especially for patients with highly active disease, have been incorporated into the Clinical Protocol and Therapeutic Guidelines of the Brazilian Unified Health System updated in 2021. The use of these highly effective drugs, such as natalizumab and alemtuzumab, is associated with a better prognosis. Despite the high cost of multiple sclerosis treatment for the Brazilian Unified Health System, there are no national studies evaluating the impact of this update on the pattern of medication dispensing. Purpose: To compare the pattern of medication dispensing for multiple sclerosis before and after the 2021 update of the Clinical Protocol and Therapeutic Guidelines; to analyze regional inequalities in the dispensing of disease-modifying drugs; to evaluate the relationship between the distance traveled by patients from their municipality of residence to the dispensing center and the dispensing of highly effective therapies in the Brazilian Unified Health System, using big data tools. Methods: An observational study based on administrative data from authorizations for highly complex outpatient procedures in the Brazilian Unified Health System Outpatient Information System, covering the period from 2019 to 2023, including patients diagnosed with multiple sclerosis. The following variables were analyzed: National Health Card number, disease-modifying drug, municipality of residence, and municipality of the dispensing center. The pattern of medication dispensing was evaluated using time series and quasi-Poisson regression models, with a descriptive and comparative approach between the periods before and after the 2021 protocol update, at the national, regional, and state levels. The distance traveled between the municipality of residence and the dispensing center was estimated using a geographic routing tool. Statistical analysis included augmented Dickey-Fuller, Cox-Stuart, Fisher’s g, Kruskal-Wallis, and Spearman correlation tests. Analyses were performed using R software (p<0.05). Results: Between 2019 and 2023, the number of multiple sclerosis patients treated by the Brazilian Unified Health System increased by 25.91%, with 71.98% being women in 2023. After the 2021 protocol update, a heterogeneous change in the pattern of medication dispensing in Brazil was observed. There was an increase in the dispensing of natalizumab (+44.5%), fingolimod (+15.8%), teriflunomide (+32.5%), and dimethyl fumarate (+53.1%), concomitant with a reduction in beta-interferons (-40.3%) and glatiramer acetate (-27.6%) (all with p<0.001). Regionally, there was an increase in the dispensing of natalizumab in all regions, with the North (+82%; p=0.042) and Northeast (+52%; p=0.039) standing out. The reduction in beta-interferons was significant only in the North region (-41.9%; p=0.049). The greatest distance traveled by patients was observed in the Central-West region (median: 234.06km [129.99-375.36]). In the analysis by federative units, no association was observed between the distance traveled by patients and the proportion of natalizumab dispensing (?=0.157; p=0.434). In the Amazon Basin, the greatest distance traveled by patients was recorded in Amazonas (414.79 km [154.82–807.57]), with no association with the proportion of natalizumab dispensing (?=0.36; p=0.444). Conclusions: The 2021 protocol update had a heterogeneous impact on the dispensing of disease-modifying drugs in Brazil, highlighting persistent regional inequalities in access to multiple sclerosis treatment. The absence of an association between the distance traveled by patients and the dispensing of more effective therapies suggests that structural, organizational, and professional training factors exert a more relevant influence on access to these treatments than geographical distance. |
| publishDate |
2026 |
| dc.date.issued.fl_str_mv |
2026 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
masterThesis |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://repositorio.einstein.br/publicacao/172733 oai:repositorio.einstein.br:172733 |
| url |
https://repositorio.einstein.br/publicacao/172733 |
| identifier_str_mv |
oai:repositorio.einstein.br:172733 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Faculdade Israelita de Ciências da Saúde Albert Einstein |
| dc.publisher.program.fl_str_mv |
Acadêmico em Ciências da Saúde |
| dc.publisher.country.fl_str_mv |
Brasil |
| publisher.none.fl_str_mv |
Faculdade Israelita de Ciências da Saúde Albert Einstein |
| dc.source.none.fl_str_mv |
reponame:Repositório Einstein de Produção Intelectual (REPI) instname:Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE) instacron:SBIBAE |
| instname_str |
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE) |
| instacron_str |
SBIBAE |
| institution |
SBIBAE |
| reponame_str |
Repositório Einstein de Produção Intelectual (REPI) |
| collection |
Repositório Einstein de Produção Intelectual (REPI) |
| repository.name.fl_str_mv |
Repositório Einstein de Produção Intelectual (REPI) - Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE) |
| repository.mail.fl_str_mv |
repositorioinstitucional@einstein.br |
| _version_ |
1880933137595236352 |